{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Heavily pretreated SCLC patients and patients with a history of pneumonitis may be at', 'increased risk, and careful monitoring for signs and symptoms of pneumonitis is', 'important. The risk of pneumonitis is increased with prior radiation to lung.', 'In general, signs and symptoms coinciding with or preceding pneumonitis may include', 'new or worsening cough, chest pain and/or shortness of breath, fever, and radiographic', 'changes (reticular markings, ground glass opacities). Protocol defined disease', 'assessments provide the opportunity for on study pulmonary monitoring with \"gold', 'standard\" diagnostic method for detection of pneumonitis. The protocol allows for', 'additional imaging per physician discretion for signs and symptoms of pulmonary', 'toxicity.', 'The diagnosis of drug induced pneumonitis is one of exclusion. Other etiologies', 'including infection, which is a common cause of pulmonary infiltrates with clinical and', 'radiographic appearance similar to drug-induced pneumonitis, need to be carefully', 'considered and excluded before the diagnosis of drug induced pneumonitis can be', 'established.', 'If pneumonitis is suspected, close monitoring including additional laboratory and imaging', 'investigation per institutional guidelines may be necessary. Systemic corticosteroids may', 'be beneficial for rapidly progressive or more severe pneumonitis. For events of Grade 1', 'pneumonitis close monitoring is recommended; while dose modifications for Grade 2 and', 'discontinuation of Rova-T for Grades 3 and 4 are required. Please see Table 5.', '184']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Section 7.0 Protocol Deviations', 'Contact Information previously read:', 'Primary Contact:', 'Alternate Contact:', 'Study Management Associate III', 'Study Project Manager I', 'AbbVie', 'AbbVie', '1 North Waukegan Road', '1 North Waukegan Road', 'North Chicago, IL 60064', 'North Chicago, IL 60064', 'Office:', 'Phone:', 'Fax:', 'Fax:', 'Email:', 'Email:', 'Has been changed to read:', 'Primary Contact:', 'Alternate Contact:', 'Study Project Manager II', 'Study Project Manager I', 'AbbVie Corporation', 'AbbVie s.r.o.', '8401 Trans-Canada Highway', 'METRONOM BUSINESS CENTER', 'Saint-Laurent, Qu\u00e9bec', 'Bucharova 2817/13, Stodulky,', 'H4S 1Z1', '158 00 Praha 5', 'Canada', 'Czech Republic', 'Phone:', 'Phone:', 'Fax:', 'Fax:', 'Email:', 'Email:', 'Section 8.1 Statistical and Analytical Plans', 'Second paragraph previously read:', 'Two analyses are planned for this study. The first will be performed when at least', '407 progression-free survival (PFS) events, assessed by a Central Radiographic', '185']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Assessment Committee (CRAC) according to RECIST v1.1, and at least 239 deaths have', 'occurred in subjects with DLL3high The second analysis will be performed when at least', '319 deaths have occurred in subjects with DLL3high', 'Has been changed to read:', 'The primary endpoints of OS and progress free survival (PFS) assessed by a Central', 'Radiographic Assessment Committee (CRAC) according to RECIST v1.1 in DLL3 high', 'patients will be analyzed at the same time after observing at least 319 OS events. It is', 'expected at approximately 420 PFS events will be observed at the time of the primary', 'analysis.', 'Section 8.1 Statistical and Analytical Plans', 'First and second bullet previously read:', 'DLL3high Set: It includes all randomized subjects with DLL3 high Subjects', 'will be classified according to the treatment arm to which they are randomized', 'regardless the actual treatment received, following intent-to-treat principle.', 'The DLL3 high set will be the primary analysis set for the analysis of efficacy', 'endpoints.', 'Randomized Set: It includes all randomized subjects, with subjects grouped', 'according to the treatment arm to which they are randomized regardless the', 'actual treatment received, following intent-to-treat principle. The randomized', 'set will be used for supportive analysis of efficacy endpoints.', '186']\n\n###\n\n", "completion": "END"}